Redwood Bioscience, Inc.

R.p.scherer Technologies, Inc.

Other

Merck Sharp + Dohme Corp.

Optimer Pharmaceuticals, Inc.

Redwiid Bioscience, Inc.

Redwood Biosciences, Inc.

David Rabuka

Romas Alvydas Kudirka

Aaron Edward Albers

Robyn M Barfield

Gregory W deHart

Albert W Garofalo

Penelope M Drake

Jesse M McFarland

Jeanne E Baker

Patrick Holder

Yun Cheol Kim

Stepan Chuprakov

Chao Bai Huang

Mark Alan Breidenbach

Francis Joseph Carr

Robert George Edward Holgate

Albert W Garafalo

Youe-Kong Shue

Chan-Kou Hwang

Yu-Hung Chiu

Alex Romero

Kenneth Marby

Chang-Hsing Liang

Steve Sucheck

Sulan Yao

Gregory W Dehart

Junjie Liu

Yoshitaka Ichikawa

Maxine Bauzon

Yoshi Ichikawa

Jonathan James Duffield

Ayodele O Ogunkoya

Jonathan Duffield

Robert George Holgate

Jeanne Baker

Yoshiaki Ichikawa

Antibodies that include a sulfatase motif-containing tag in a constant region of an immunoglobulin (Ig) heavy chain polypeptide are disclosed. The sulfatase motif can be converted by a formylglycine-generating enzyme (FGE) to produce a formylglycine (fGly)-modified Ig heavy chain polypeptide. An fGly-modified Ig heavy chain polypeptide of the antibody can be covalently and site-specifically bound to a moiety of interest to provide an antibody conjugate. The disclosure also encompasses methods of production of such tagged Ig heavy chain polypeptides, fGly-modified Ig heavy chain polypeptides, and antibody conjugates, as well as methods of use of same.

Antibody conjugates and methods of making and using the same

The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Hydrazinyl-pyrrolo compounds and methods for producing a conjugate

The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.

Antibody specific for CD22 and methods of use thereof

The present disclosure provides anti-CD22 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Anti-CD22 antibody-maytansine conjugates and methods of use thereof

The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Anti-HER2 antibody-maytansine conjugates and methods of use thereof

The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.

Activated formylglycine-generating enzymes and methods of producing and using the same

The present disclosure provides antibody-drug conjugate structures, that include a cleavable linker having a sulfatase-cleavable moiety. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Sulfatase-cleavable linkers for antibody-drug conjugates

The present disclosure provides antibodies specific for Mucin 1. Nucleic acids that encode one or both of the variable chains of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of an antibody of the present disclosure, where the antibody is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells of the cell proliferative disorder. The antibodies are also useful in various diagnostic, and monitoring applications, which are also provided.

Antibody specific for Mucin-1 and methods of use thereof

The present disclosure provides anti-CD25 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Anti-CD25 antibody-maytansine conjugates and methods of use thereof

Antibodies that include a sulfatase motif-containing tag in a constant region of an immunoglobulin (Ig) light chain polypeptide are disclosed. The sulfatase motif can be converted by a formylglycine-generating enzyme (FGE) to produce a formylglycine (fGly)-modified Ig light chain polypeptide. An fGly-modified Ig light chain polypeptide of the antibody can be covalently and site-specifically bound to a moiety of interest to provide an antibody conjugate. The disclosure also encompasses methods of production of such tagged Ig light chain polypeptides, fGly-modified Ig light chain polypeptides, and antibody conjugates, as well as methods of use of same.

The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.

Hydrazinyl-indole compounds and methods for producing a conjugate

The present disclosure provides conjugate structures and hydrazinyl-substituted heteroaryl compounds used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates and compounds, as well as methods of using the same.

Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate

Growing community of inventors

Kensington, CA, United States of America

David Rabuka